Idaho Society of Cancer Oncology

Welcome

The Idaho Society of Clinical Oncology (ISCO) represents Idaho physicians and related health care professionals who care for cancer patients. The Society is a non-profit corporation devoted to the improvement of hematologic and oncologic care of patients.

The Benefits of Membership

Membership in the Society is open to all professionals whose primary endeavor is the delivery of oncology care,  including physicians, nurse practitioners, physician assistants and pharmacists. Membership is restricted to those individuals primarily delivering care in the State of Idaho and is FREE to qualified professionals

Join Today

New ASCO Policy Brief: Co-Pay Accumulators and Co-pay Maximizers
Co-pay accumulators and co-pay maximizers have been an area of concern amongst State Affiliate Council members.  ASCO has created a new informational policy brief to help explain these programs and provide guidance regarding its position as an organization.  The brief can be accessed by clicking below.

Click here for more information

New Survey Seeks Provider Input on Clinical Trial Enrollment
ASCO is participating in a joint initiative from the American Cancer Society's Cancer Action Network in conjunction with the Association of Community Cancer Centers and the Oncology Nursing Society.  Click below to access the survey.

Click here for the survey

Educate and Support Your Patients with ASCO Answers Materials
Recently, State Affiliate presidents and executive directors received a mailing from Cancer.Net that included patient education materials that you and your members may find useful. These materials, along with additional resources that can be found on Cancer.Net give your patients ASCO-approved information on diagnosis, treatment, side effects, and psychosocial effects of cancer.  The ASCO Answers series includes fact sheets, booklets on specific topics in cancer care, and comprehensive, patient-friendly guides. These easy-to-read materials cover breast cancer, colorectal cancer, non-small cell lung cancer, small cell lung cancer, prostate cancer, cancer survivorship, caregiving, palliative care, managing cancer-related pain, advanced cancer care planning, and much more.  ASCO members save 20 percent.  All orders include free domestic shipping. 

Order printed copies online at the ASCO Store.

 

CMS Proposes New Electronic Prior Authorization Process to Speed Access to Care
CMS recently issued a proposed rule to update and streamline the prior authorization process under Medicare Part D.

Find out more
 
 

August 2019 Advocacy Update

Click here for more.

 

Upcoming Events

ISCO Fall Meeting
November 1-2, 2019
The Grove Hotel | Boise


Walmart to Measure Doctor Quality in Local Markets
Walmart is rolling out an effort to measure the quality of community doctors who treat tens of thousands of its employees in the retailer’s latest effort to make sure its workers get the right care, in the right place and at the right time.

Find out more

CMS to Collect 340B Drug Cost Information
The CMS issued a notice on September 26th that it will collect information from hospitals participating in the 340B drug discount program about the prices they pay for eligible drugs.

Click here for more

Cancer Drugs Account for 27% of All New Drug Approvals in the US
Cancer drugs currently account for 27% of all new drug approvals in the United States since 2010, a dramatic increase from the 4% share of the 1980s, a newly completed analysis from the Tufts Center for the Study of Drug Development shows.

Click here for more

New Technology Add-on Payment: Impact on CAR T-cell Therapy Reimbursement
On August 2, the Centers for Medicare & Medicaid Services (CMS) released the Hospital Inpatient Prospective Payment System (IPPS) final rule for fiscal year (FY) 2020.

Click here for more.

CMS Expands CAR T-cell Therapy Coverage for Medicare Beneficiaries
The Centers for Medicare & Medicaid Services (CMS) announced that Medicare will now cover all Food and Drug Administration-approved Chimeric Antigen Receptor T-cell (CAR T-cell) therapy delivered in inpatient facilities.  This nationwide Medicare coverage increase for CAR T-cell therapy also opens the door for patients to receive treatment in outpatient health care facilities that are enrolled in FDS risk evaluation and mitigation strategies with expertise in delivering cellular therapies, and covers CAR T-cell therapy for off-label uses that are recommended by CMS-approved compendia.

Read more here

Sharing Hospital Outpatient Payment Proposal Maintains 340B Cuts, Addresses Price Transparency and Prior Authorization
On July 29, the Centers for Medicare & Medicaid Services (CMS) released its proposed rule for reimbursement under the Hospital Outpatient Prospective Payment System (HOPPS) in 2020. ASCO is still analyzing the proposal and will provide more information to members as soon as possible.

Click here for more.

Economic Cost of Cancer in U.S. Tops $94B Annually According to a Study
State-by-state variations in cancer deaths suggest that effective cancer prevention and treatment could yield economic benefits, according to a study published in JAMA Oncology.

Click here for more.